Lords Mark Industries has announced a strategic shift to prioritize its MedTech business, with plans to rebrand as 'Lords Med' and potentially spin off its renewable energy division. The company projects FY27 revenue at Rs 1,550 crore and aims to meet Minimum Public Shareholding requirements by diluting promoter stakes. Significant capital investment is planned for a new manufacturing facility in Lucknow to boost domestic production capabilities.
Lords Mark Industries Outlines FY27 Growth and Restructuring Roadmap
Revenue guidance for FY27 is set at Rs 1,550 crore with a 12.8% PAT margin.
Management plans to split its renewable energy business and focus on high-growth MedTech.
Reader Takeaway: Growth is driven by aggressive MedTech expansion, though restructuring and MPS compliance remain key operational hurdles.
What just happened
Lords Mark Industries has signaled a major strategic pivot, rebranding as 'Lords Med' to concentrate on the medical technology sector. As part of this transition, the company is evaluating the separation of its renewable energy arm, which currently accounts for 60% of its revenue. The management has guided for a consolidated revenue of Rs 1,550 crore in FY27, with EBITDA margins projected at 20.8%.
Why this matters
The pivot reflects a move toward higher-margin, specialized technology segments like dialysis machines and genomics testing. The company aims to leverage government health initiatives, specifically for sickle-cell screening. Investors are tracking this transition as the company attempts to improve its cash flow profile and scale its presence both in India and abroad.
Governance and MPS Update
To align with market regulatory requirements, the company has appointed Nuvama as its merchant banker to meet Minimum Public Shareholding (MPS) standards. Plans involve diluting the promoter stake from its current level to 75%. This will be executed through a combination of a 3% Offer for Sale (OFS) and 2% via additional equity or preference instruments.
Capex and Expansion
Lords Mark is committing Rs 300-350 crore in capital expenditure over the next three years. The primary focus is a new manufacturing plant in Lucknow for IVD and biochemistry analyzers. This investment is intended to lower import reliance and consolidate the company's production footprint.
Risks to watch
Investors should monitor the timeline for the renewable energy division spin-off and the execution of the Lucknow manufacturing plant. Additionally, the company is managing a Rs 450 crore receivables balance, which management has attributed to recent merger activity but will require consistent monitoring to ensure operating cash flows turn positive by the projected FY27 timeline.